Literature DB >> 33246092

Sox9/INHBB axis-mediated crosstalk between the hepatoma and hepatic stellate cells promotes the metastasis of hepatocellular carcinoma.

Yu Chen1, Baowei Qian1, Xiaolin Sun1, Zhiqian Kang1, Zhen Huang1, Zhi Ding1, Lei Dong1, Jiangning Chen2, Junfeng Zhang3, Yuhui Zang4.   

Abstract

The activation of hepatic stellate cells (HSCs) and liver fibrosis in the peri-tumoral tissue contributes to the progression of hepatocellular carcinoma (HCC). However, the mechanisms underlying the crosstalk between hepatoma and peri-tumoral HSCs remain elusive. We found that the Sox9/INHBB axis is upregulated in HCC and is associated with tumor metastasis. Using gain- and loss-of-function approaches, we revealed that the Sox9/INHBB axis promotes the growth and metastasis of an orthotopic HCC tumor by activating the peri-tumoral HSCs. Mechanistically, Sox9 induces INHBB expression by directly binding to its enhancer, thus aiding in the secretion of activin B from hepatoma cells, and in turn, promoting the activation of the surrounding HSCs through activin B/Smad signaling. Furthermore, inhibition of activin B/Smad singaling attenuates the fibrotic response in the peri-tumoral tissue and decreases the incidence of metastasis. Finally, clinical analyses indicated a positive correlation between Sox9 and INHBB expression in HCC specimens and identified the Sox9/INHBB axis as a positive regulator of liver fibrosis. In conclusion, Sox9/INHBB axis-mediated crosstalk between hepatoma cells and HSCs induces a fertile environment favoring HCC metastasis, thereby exhibiting as a potential therapeutic target.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Activin B; Liver fibrosis; Paracrine; Peri-tumoral tissue

Mesh:

Substances:

Year:  2020        PMID: 33246092     DOI: 10.1016/j.canlet.2020.11.025

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  Development and Validation of a Robust Immune-Related Prognostic Signature for Gastric Cancer.

Authors:  Junyu Huo; Liqun Wu; Yunjin Zang
Journal:  J Immunol Res       Date:  2021-04-30       Impact factor: 4.818

2.  Metastatic profiling of HER2-positive breast cancer cell lines in xenograft models.

Authors:  Yuxuan Han; Kazushi Azuma; Shinya Watanabe; Kentaro Semba; Jun Nakayama
Journal:  Clin Exp Metastasis       Date:  2022-02-01       Impact factor: 5.150

3.  Immune Signature-Based Risk Stratification and Prediction of Immunotherapy Efficacy for Bladder Urothelial Carcinoma.

Authors:  Fangfang Liang; Yansong Xu; Yi Chen; Huage Zhong; Zhen Wang; Tianwen Nong; Jincai Zhong
Journal:  Front Mol Biosci       Date:  2021-12-24

Review 4.  Advance of SOX Transcription Factors in Hepatocellular Carcinoma: From Role, Tumor Immune Relevance to Targeted Therapy.

Authors:  Xiangyuan Luo; Xiaoyu Ji; Meng Xie; Tongyue Zhang; Yijun Wang; Mengyu Sun; Wenjie Huang; Limin Xia
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

5.  Single-cell transcriptomics analysis reveals intratumoral heterogeneity and identifies a gene signature associated with prognosis of hepatocellular carcinoma.

Authors:  Jialu Liang; Wenhui Chen; Jianwen Ye; Chen Ni; Wenlong Zhai
Journal:  Biosci Rep       Date:  2022-02-25       Impact factor: 3.840

Review 6.  Resident Immune Cells of the Liver in the Tumor Microenvironment.

Authors:  Yunjie Lu; Shiying Ma; Wei Ding; Pengcheng Sun; Qi Zhou; Yunfei Duan; Kurt Sartorius
Journal:  Front Oncol       Date:  2022-07-19       Impact factor: 5.738

Review 7.  Advances of cancer-associated fibroblasts in liver cancer.

Authors:  Hao Peng; Erwei Zhu; Yewei Zhang
Journal:  Biomark Res       Date:  2022-08-16

8.  Curcumin and berberine co-loaded liposomes for anti-hepatocellular carcinoma therapy by blocking the cross-talk between hepatic stellate cells and tumor cells.

Authors:  Jingliang Wu; Cuiping Qi; Hao Wang; Qing Wang; Jingui Sun; Jinping Dong; Guohua Yu; Zhiqin Gao; Bo Zhang; Guixiang Tian
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.